Moreover, a combination of the GSI PF-03084014 and irinotecan effectively reduced tumor growth in colon cancer preclinical explant model and suppressed the growth of ALDH+ tumor-initiating cells [535]. This evidence concerns the gene LDHA and neoplasm.